What Is Semax? A Stress-Hormone Fragment Re-Tuned for the Brain

In the early 1980s, Russian researchers took a fragment of one of the body’s most famous stress hormones — adrenocorticotropic hormone, or ACTH — and began re-engineering it. They were not interested in the hormone’s headline job, the cascade that floods the body with cortisol. They were chasing a quieter, stranger property buried in a short stretch of its amino-acid sequence: a signal that seemed to speak directly to the brain. The result of that work, after a series of chemical modifications, was Semax — a seven-residue peptide that keeps the neuro-active whisper of a stress hormone while discarding the hormonal shout.

What exactly is Semax?

Semax is a synthetic heptapeptide — a chain of just seven amino acids, sequence Met-Glu-His-Phe-Pro-Gly-Pro. The first four of those residues correspond to the ACTH(4-7) fragment of adrenocorticotropic hormone; the trailing Pro-Gly-Pro tail is a design feature intended to make the short peptide more robust than the bare fragment alone. In the literature it is described as an ACTH(4-7) analogue with nootropic properties (often written ACTH(4-10) analogue in older papers), and that lineage is the whole point: ACTH-derived fragments have long been known to influence learning and attention independently of the adrenal-stimulating action that makes ACTH a stress hormone in the first place.²

Think of ACTH as a single instruction shouted down two corridors at once — one leading to the adrenal glands, one leading to the brain. Semax is what you get when you keep only the brain-facing message and amplify it. Crucially, the N-terminal end of the peptide matters: modifying it changes the nootropic effect, which tells researchers the activity is structurally specific rather than a generic peptide artefact.³

What does the research on Semax actually show?

The bulk of the Semax literature lives in rodent models, and within that world it is unusually well characterised. On the cognitive side, Semax has been reported to activate dopaminergic and serotonergic systems in the brain, the neurotransmitter circuits most associated with motivation, mood and attention — the mechanistic basis for its description as a nootropic.²

The most developed body of work, though, concerns neuroprotection. In rat models of cerebral ischaemia and stroke, Semax and related ACTH-like peptides appear to compensate for ischaemia-disrupted gene expression, nudging the injured brain’s transcriptional programme back toward a protective state.⁷⁹ Proteomic profiling has reinforced this, with brain-protein signatures consistent with a protective effect after ischaemia-reperfusion injury,¹⁴ and Semax has been shown to suppress transcripts for pro-inflammatory mediators after reversible brain ischaemia.¹⁵ A related inflammatory thread runs through spinal-cord-injury models, where the peptide has been reported to raise anti-inflammatory cytokines such as IL-4, IL-10 and IL-13¹¹ while modulating pro-inflammatory IL-6 and IL-8,¹² sketching a consistent picture of an immunomodulatory tilt toward repair.

A separate and intriguing thread links Semax to Alzheimer’s-model research. The peptide can act as a copper chelator, and because copper catalyses the formation of reactive oxygen species and influences the aggregation of amyloid-beta (Aβ), this chemistry matters: Semax has been reported to decrease copper-catalysed ROS and Aβ cytotoxicity,⁸ to affect copper-induced Aβ aggregation in membrane models,¹³ and, with a derivative, to correct impairments in an animal model of Alzheimer’s disease.⁵ There is also evidence for antidepressant-like and antistress effects in chronically stressed male rats,¹⁰ alongside more recent work probing intracellular calcium dynamics in neurons⁶ and recovery after spinal cord injury in mice.⁴

Semax at a glance: an ACTH(4-7)-derived heptapeptide studied across cognition, neuroprotection and mood — predominantly in animal models.

Which pathways has Semax been studied against in animal models?

The most-cited molecular feature is its reported effect on neurotrophins, the brain’s own survival-and-plasticity signals. In rats, the heptapeptide was reported to stimulate expression of brain-derived neurotrophic factor (BDNF) in different brain areas in vivo,¹⁸ and in the rat hippocampus it was reported to regulate both BDNF and its receptor trkB.¹⁹ After experimental cerebral ischaemia, Semax and its C-terminal Pro-Gly-Pro peptide were reported to activate transcription of neurotrophins and their receptor genes, a coordinated transcriptional response rather than a single switch.²⁰

A note on nomenclature, because both names appear in the literature: the sequence Met-Glu-His-Phe-Pro-Gly-Pro is ACTH(4-7) extended with a Pro-Gly-Pro tail, and the compound is variously described as an ACTH(4-7) or ACTH(4-10) analogue. A second line of work runs through the dopaminergic system, which is associated with motivation and attention. In rats, Semax was reported to potentiate the effect of D-amphetamine on extracellular dopamine in the striatum and on locomotor activity in mice,²¹ and it showed neuroprotective effects in an MPTP model of dopamine-system damage.²²

All entries are rodent or cell-system findings. Semax is a registered medicine in Russia and has no EU or US marketing authorisation; here it is a research-use-only material.

Is Semax approved as a medicine?

This is where the picture demands honesty. Semax is a registered medicine in Russia, where it has seen clinical use for years. But it is not approved in the EU or the US. In Europe and North America it has no marketing authorisation and exists purely as a research-use-only material. Its regulatory profile is also actively in flux: Semax is among the peptides slated for review by the FDA’s Pharmacy Compounding Advisory Committee in July 2026, a process that may further clarify its status in the US compounding landscape.

How strong is the evidence really?

Here is the honest accounting that a scientifically literate reader deserves. The preclinical case for Semax is extensive and mechanistically coherent: independent labs publishing in peer-reviewed Western journals — the British Journal of Pharmacology,⁴ Acta Naturae,⁵ ACS Chemical Neuroscience,¹³ and several others⁷⁸¹⁰¹⁴ — continue to report effects on neuroprotection, copper chemistry and stress behaviour. That is more than can be said for many fashionable peptides.

But two caveats are essential. First, the evidence is overwhelmingly animal-model and in-vitro; the cognitive and neuroprotective findings describe rodents and cell systems, not humans. Second, much of the foundational work — and the clinical experience that underpins Russian registration — originates from Russian research groups and Russian-language literature, with comparatively limited independent Western clinical validation. None of this makes the work unserious. It does mean Semax should be treated as investigational, a compound whose human profile remains far less settled than its preclinical CV suggests. For comparison, you can read our primer on its close relative Selank, or the broader nootropic-peptides hub for how these molecules sit relative to one another.

The evidence in numbers. A PubMed search run on 23 September 2026 for Semax under its literature names returns 208 records. 47 are indexed with the MeSH term “Humans”, which also covers work on human cells and tissue; 145 involve animals only; 4 are tagged as clinical trials; and 39 were published from 2020 onwards.¹⁶ ClinicalTrials.gov, the largest international trial registry, lists no registered study of Semax.¹⁷ For a compound registered as a medicine in Russia, the internationally registered trial record is empty; most of the controlled human work sits in Russian-language journals indexed only in part.

What should a researcher actually care about?

For laboratory work, the decisive variables are not marketing claims but molecular reality: is the material in the vial actually the Met-Glu-His-Phe-Pro-Gly-Pro heptapeptide, at the stated purity, free of the truncated sequences and process impurities that plague poorly made peptides? A seven-residue chain leaves little room for ambiguity — either the sequence is correct or it is not — and that is exactly why identity and purity verification matter so much. Every batch should arrive with a Certificate of Analysis documenting HPLC purity and mass-spectrometric confirmation of identity. Semax is supplied strictly for research use only: it is not a medicine, not for human or veterinary use, and not intended for consumption. Its value to a researcher lies entirely in being precisely, verifiably what the label says — the same standard we apply to every compound, including our Semax research material.